Bogart M, Bengtson LGS, Johnson MG, et al.

Title: Outcomes following initiation of triple therapy with fluticasone furoate/umeclidinium/vilanterol versus multiple-inhaler triple therapy among Medicare Advantage with part D beneficiaries and those commercially enrolled for health care insurance in the United States.

Citation: Int J Chron Obstruct Pulmon Dis
2024;19:97–110.

Country: USA | Indication: COPD

This is a GSK-supported study

http://tago.ca/38226396
Scan to access the publication or visit
http://tago.ca/38226396